[Asia Economy Reporter Lee Gwan-joo] GC Green Cross announced on the 30th that it has signed a strategic business agreement with JP Bio for formulation development.
JP Bio is a formulation development company that has successfully developed numerous improved new drugs and generic finished pharmaceuticals. Through this contract, GC Green Cross will receive formulation technology from JP Bio to proceed with product development, production, and commercialization.
GC Green Cross plans to steadily expand its synthetic drug portfolio by securing JP Bio's excellent formulation technology competitiveness.
A JP Bio official stated, "Through this business partnership, we aim to achieve tangible results in the stable domestic supply of high value-added pharmaceuticals and global expansion."
Meanwhile, GC Green Cross has been focusing on targeting the synthetic drug market, recently obtaining product approval for 'Rozetelpine,' a four-drug combination for hypertension and hyperlipidemia.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
